Table 3 Hazard ratio of endometrial cancer by birthweight among 71 751 participants of the Nurses' Health Study during follow-up from 1976–2004 stratified by menopausal status

From: Longitudinal study on birthweight and the incidence of endometrial cancer

   

HR (95% CI)

Birthweight (g)

Person-years

No. of cases

Age-adjusted

Covariate –adjusted I a

Covariate –adjusted II b

Covariate –adjusted III c

Premenopausal

 ⩾3863

72535

14

1.0

1.0

1.0

1.0

 3182–<3863

280538

43

0.77 (0.41–1.44)

0.79 (0.42–1.48)

0.90 (0.46–1.78)

0.95 (0.47–1.91)

 2500–<3182

194984

31

0.85 (0.44–1.63)

0.79 (0.41–1.54)

0.87 (0.43–1.76)

0.95 (0.46–1.97)

 <2500

67533

8

0.59 (0.24–1.42)

0.45 (0.17–1.19)

0.40 (0.14–1.15)

0.43 (0.14–1.28)

 P for trend

  

0.37

0.18

0.17

0.27

Postmenopausal

 ⩾3863

130992

70

1.0

1.0

1.0

1.0

 3182–<3863

409653

264

1.21 (0.93–1.58)

1.21 (0.93–1.58)

1.20 (0.92–1.57)

1.23 (0.94–1.61)

 2500–<3182

284140

170

1.12 (0.85–1.48)

1.12 (0.85–1.49)

1.10 (0.83–1.46)

1.17 (0.87–1.56)

 <2500

102233

67

1.21 (0.86–1.69)

1.21 (0.84–1.74)

1.19 (0.82–1.72)

1.22 (0.84–1.77)

 P for trend

  

0.46

0.48

0.58

0.38

  1. aHazard ratio (HR) and 95% confidence interval (CI) were adjusted for age (continuous), premature birth (yes, no), birth order (first, second, third, fourth or above), duration of being breast fed in infancy (no, ⩽3, 4–8, ⩾9 months), and family history of endometrial cancer (yes, no).
  2. bHR and 95% CI were adjusted for age (continuous), premature birth (yes, no), birth order (first, second, third, fourth or above), duration of being breast fed in infancy (no, ⩽3, 4–8, ⩾9 months), and family history of endometrial cancer (yes, no), age at menarche (⩽10, 11, 12, 13, 14, 15+ years), current and past contraceptive use (never, past<5 years, past⩾5 years, current< 5years, current⩾5 years), parity (1,2,3,4+), age at first birth (⩽24, 25–30, 30+ years), age at last birth (⩽24, 25–29, 30–34, 35–40, >40 years), physical activity (<3, 3–8, 9–17, 18–26, 27–41, 42+ mets per week), cigarette smoking (never, 1–20, 21–40, 41+ pack–years), tamoxifen use (never, past and <5 years, past and ⩾5 years, current and <5 years, current and ⩾5 years). Age at menopause (<50, 50–52, 53+ years), and postmenopausal hormone use (never, past and <5 years, past and ⩾5 years, current and <5 years, current and ⩾5 years) were additionally adjusted for in the analysis of postmenopausal endometrial cancer.
  3. cHR and 95% CI were adjusted for age (continuous), premature birth (yes, no), birth order (first, second, third, fourth or above), duration of being breast fed in infancy (no, ⩽3, 4–8, ⩾9 months), and family history of endometrial cancer (yes, no), age at menarche (⩽10, 11, 12, 13, 14, 15+ years), current and past contraceptive use (never, past<5years, past⩾5years, current<5 years, current⩾5 years), parity (1,2,3,4+), age at first birth (⩽24, 25–30, 30+ years), age at last birth (⩽24, 25–29, 30–34, 35–40, >40 years), physical activity (<3, 3–8, 9–17, 18–26, 27–41, 42+ mets per week), cigarette smoking (never, 1–20, 21–40, 41+ pack-years), tamoxifen use (never, past and <5 years, past and ⩾5 years, current and <5 years, current and ⩾5 years), BMI (continuous in kg m−2), BMI at age 18 (continuous in kg m−2), and somatotype at age 5 and age at 10 (ranked from 1–9). Age at menopause (<50, 50–52, 53+ years), and postmenopausal hormone use (never, past and <5 years, past and ⩾5 years, current and <5 years, current and ⩾5 years) were additionally adjusted for in the analysis of postmenopausal endometrial cancer.
Back to article page